Cailin Conner

Articles by Cailin Conner

Cailin ConnerMyelofibrosis | October 8, 2024
The phase III PERSIST-2 study compared symptom results from pacritinib with those of best available therapy and ruxolitinib.
Cailin ConnerMyelofibrosis | October 8, 2024
Patients' genomic profiles and baseline laboratory values have implications for their treatment outcomes with these agents.
Cailin ConnerMyelofibrosis | October 8, 2024
The International Prognostic Scoring System, Dynamic International Prognostic Scoring System, and other models were applied.
Cailin ConnerMyelofibrosis | October 9, 2024
A retrospective study found momelotinib plus pacritinib led to reduced need for red blood cell transfusion in patients.
Cailin ConnerChronic Lymphocytic Leukemia | September 20, 2024
Fixed-duration ibrutinib plus venetoclax provides durable PFS in patients with CLL.
Cailin ConnerChronic Lymphocytic Leukemia | September 20, 2024
Ibrutinib provides significantly longer PFS and OS benefits in CLL when compared to chlorambucil.
Cailin ConnerChronic Lymphocytic Leukemia | September 20, 2024
Oral targeted inhibitors are a viable treatment for patients with CLL with severe renal dysfunction.
Cailin ConnerChronic Lymphocytic Leukemia | September 20, 2024
Switching rates within 60 days were lower for patients treated with zanubrutinib compared with acalabrutinib and ibrutinib.
Cailin ConnerAcute Myeloid Leukemia | September 6, 2024
Quizartinib significantly improves long-term survival in FLT3-ITD+ AML by achieving deep and sustained reductions in MRD.
Cailin ConnerAcute Myeloid Leukemia | September 6, 2024
Combining HMAs with venetoclax significantly improves remission rates and survival but requires more healthcare resources.
Cailin ConnerAcute Myeloid Leukemia | September 9, 2024
SLC40A1 mRNA levels were significantly higher in AML patients compared with controls and were associated with poorer OS.
Cailin ConnerAcute Myeloid Leukemia | September 6, 2024
Achieving complete hematologic recovery before subsequent treatment cycles is associated with improved survival outcomes.
Cailin ConnerMantle Cell Lymphoma | October 6, 2023
The investigators conceded the longer follow-up is needed but the results are promising.
Cailin ConnerChronic Lymphocytic Leukemia | September 25, 2023
The primary endpoints of the phase III ELEVATE-RR study were PFS, AEs, and events of clinical interest.
Cailin ConnerChronic Lymphocytic Leukemia | September 22, 2023
Reseserchers with the German CLL Study Group conducted a prospective analysis of karyotype complexity in patients with CLL.
Cailin ConnerChronic Lymphocytic Leukemia | September 25, 2023
Patients with mutated IGHV had a median PFS of 14.6 years compared with 4.2 years in patients with unmutated IGHV.
Cailin ConnerPrint | October 11, 2023
Japan's MHLW grants orphan drug designation to treatments designed for fewer than 50,000 patients.
Cailin ConnerMeeting News | September 10, 2023
Noteworthy regional disparities were noticed in treatment strategies.
Cailin ConnerChronic Lymphocytic Leukemia | September 10, 2023
Investigators from the Mayo Clinic identified 145 patients with CLL who were treated between 2014-2021.
Cailin ConnerMeeting News | September 10, 2023
The need for phlebotomies substantially decreased in those who received ruxolitinib after hydroxyurea.